The clock is ticking for Immutep Limited investors who bought shares between March 24, 2025, and March 12, 2026. July 6, 2026, is the cutoff to contact the Schall Law Firm about leading a class action lawsuit. The firm, based in Los Angeles at 2049 Century Park East, Suite 2460, is taking calls at 310-301-3335.
The lawsuit targets statements Immutep made about its TACTI-004 trial of eftilagimod alfa. According to the complaint, the company told the market it was making “strong operational progress” in a Form-K filed with the SEC on January 30, 2026.
The allegation: Immutep knew at that time the trial would fail its primary efficacy endpoints. That knowledge, if proven, would make the public statements false and misleading under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. Investors who took the company at its word now face a hard reality.
The class period spans roughly a year. Anyone who bought securities during that window and later took a loss is eligible to join the suit.
But the class has not yet been certified. Until it is, no investor is formally represented by an attorney. Those who do nothing can remain absent class members, but they forfeit any chance to lead the action.
The Schall Law Firm is offering free consultations to discuss investor rights. The firm’s statement, released June 22, frames this as a chance for shareholders to step forward. The number to call is 310-301-3335.
What happens next depends on investor response. A sharp rise in interest is expected from those who suffered losses.
The lawsuit’s success will hinge on proving Immutep deliberately concealed trial results. For the company, the stakes are high. A finding of liability could mean significant financial penalties.
For shareholders, it is a chance at recovery — but only if they act before the July deadline. The TACTI-004 trial was a key piece of Immutep’s pipeline.
Eftilagimod alfa, the drug under study, was supposed to show promise. Instead, the trial failed to meet its primary goals. The gap between what the company said publicly and what it allegedly knew internally is the core of the case.
Investors should note the mechanics of class actions. Until certification, the class does not legally exist. That means individual investors are on their own for now.
The Schall Law Firm is effectively recruiting a lead plaintiff — someone to represent the group. That person will have the most to gain or lose, depending on the outcome.
The law firm is a national player in shareholder rights litigation. Its Century Park East address places it in the heart of Los Angeles’s legal district. The phone line is open for investors to discuss their situation without charge.
For now, the case is in its early stages. No court has ruled on the merits.
No settlement is on the table. The only concrete date is July 6, 2026 — the deadline to contact the firm. After that, the window for leading the lawsuit closes.
Immutep has not publicly responded to the allegations. The company’s stock performance during the class period and after the trial results emerged will likely be a focus of discovery. Investors who held through the decline are the ones the lawsuit aims to protect.
The Schall Law Firm is clear: this is about holding the company accountable for what it said and when it said it. The complaint alleges a straightforward fraud — saying one thing while knowing another.
If proven, it would be a textbook securities violation. Investors who want to lead the charge need to pick up the phone. The number again is 310-301-3335.
The address is 2049 Century Park East, Suite 2460, Los Angeles, CA 90067. The deadline is July 6, 2026.
After that, the chance to be the face of the lawsuit is gone.
Sources
- What Triggered Immutep's Securities Class Action Lawsuit
- SueWallSt Reminds Immutep Limited Investors of the Pending …
